계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
SAB Biotherapeutics
company
About
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $14M
- Industries
- Biotechnology,Clinical Trials,Therapeutics
- Founded date
- Jun 1, 2014
- Number Of Employee
- 51 - 100
- Operating Status
- Active
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$15.42M
SAB Biotherapeutics has raised a total of
$15.42M
in funding over 2 rounds. Their latest funding was raised on
Jul 17, 2020 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 17, 2020 | Series B | $14M | 1 | — | — | Detail |
| Sep 7, 2016 | Grant | $1.42M | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
SAB Biotherapeutics is funded by 2 investors.
National Institutes of Health
and Merck
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Merck
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
